CN104619699A - 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途 - Google Patents
二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途 Download PDFInfo
- Publication number
- CN104619699A CN104619699A CN201380041462.1A CN201380041462A CN104619699A CN 104619699 A CN104619699 A CN 104619699A CN 201380041462 A CN201380041462 A CN 201380041462A CN 104619699 A CN104619699 A CN 104619699A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- shi
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JNYGOKRJVJWWEO-UHFFFAOYSA-N CC(C)NC(C(N=C(Cc(cccc1)c1Br)NC1=O)=C1O)=O Chemical compound CC(C)NC(C(N=C(Cc(cccc1)c1Br)NC1=O)=C1O)=O JNYGOKRJVJWWEO-UHFFFAOYSA-N 0.000 description 1
- OWEIWLGKINGABC-UHFFFAOYSA-N CC(C1[U]C1)N Chemical compound CC(C1[U]C1)N OWEIWLGKINGABC-UHFFFAOYSA-N 0.000 description 1
- YHHJTGGGPJUVKR-UHFFFAOYSA-N COC(C(N=C(Cc(ccc(F)c1)c1Br)NC1=O)=C1O)=O Chemical compound COC(C(N=C(Cc(ccc(F)c1)c1Br)NC1=O)=C1O)=O YHHJTGGGPJUVKR-UHFFFAOYSA-N 0.000 description 1
- UQNSPHLTFSTWRH-UHFFFAOYSA-N Cc1cccc(CS(NC(N(C)C2=O)=NC(C(NC)=O)=C2OCc2ccccc2)(=O)=O)c1 Chemical compound Cc1cccc(CS(NC(N(C)C2=O)=NC(C(NC)=O)=C2OCc2ccccc2)(=O)=O)c1 UQNSPHLTFSTWRH-UHFFFAOYSA-N 0.000 description 1
- DIPUBYIJEDEWHU-UHFFFAOYSA-N Cc1ccccc1-c1c(CC(NC2=O)=NC(C(OC)=O)=C2O)cccc1 Chemical compound Cc1ccccc1-c1c(CC(NC2=O)=NC(C(OC)=O)=C2O)cccc1 DIPUBYIJEDEWHU-UHFFFAOYSA-N 0.000 description 1
- XIHBFIQKEZJUFD-UHFFFAOYSA-N OC1=C(C(N2CCCC2)=O)N=C(Cc(cccc2)c2-c2ccccc2)NC1=O Chemical compound OC1=C(C(N2CCCC2)=O)N=C(Cc(cccc2)c2-c2ccccc2)NC1=O XIHBFIQKEZJUFD-UHFFFAOYSA-N 0.000 description 1
- GOOXCDDIQSISMJ-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2Cl)=O)N=C(Cc(cccc2)c2Br)NC1=O Chemical compound OC1=C(C(NCc(cc2)ccc2Cl)=O)N=C(Cc(cccc2)c2Br)NC1=O GOOXCDDIQSISMJ-UHFFFAOYSA-N 0.000 description 1
- LFCNLXNJPPZOPQ-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(Cc2ccccc2Br)NC1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(Cc2ccccc2Br)NC1=O LFCNLXNJPPZOPQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679968P | 2012-08-06 | 2012-08-06 | |
| US61/679,968 | 2012-08-06 | ||
| PCT/EP2013/066388 WO2014023691A1 (en) | 2012-08-06 | 2013-08-05 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104619699A true CN104619699A (zh) | 2015-05-13 |
Family
ID=49118489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380041462.1A Pending CN104619699A (zh) | 2012-08-06 | 2013-08-05 | 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8921388B2 (https=) |
| EP (1) | EP2885289A1 (https=) |
| JP (1) | JP2015524457A (https=) |
| KR (1) | KR20150039832A (https=) |
| CN (1) | CN104619699A (https=) |
| BR (1) | BR112015002516A2 (https=) |
| CA (1) | CA2879245A1 (https=) |
| HK (2) | HK1210177A1 (https=) |
| MX (1) | MX2015001478A (https=) |
| RU (1) | RU2015107803A (https=) |
| WO (1) | WO2014023691A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109503528A (zh) * | 2018-05-15 | 2019-03-22 | 天津国际生物医药联合研究院 | 一种化合物及其在抗沙粒病毒感染中的应用 |
| CN109897007A (zh) * | 2019-02-25 | 2019-06-18 | 天津国际生物医药联合研究院 | 二羟基嘧啶化合物及其应用 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2014143242A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
| PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| WO2016005330A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| EP3957627B1 (en) * | 2015-04-24 | 2024-06-19 | Shionogi & Co., Ltd | 6-membered heterocyclic derivative and pharmaceutical composition comprising same |
| MX394421B (es) | 2015-04-28 | 2025-03-24 | Shionogi & Co | Derivados de piridona policiclica sustituida y profarmaco de los mismos |
| BR112017022550B1 (pt) | 2015-04-28 | 2021-02-23 | Shionogi & Co., Ltd | derivados policíclicos de piridona substituída |
| US20170081331A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| WO2017083431A2 (en) * | 2015-11-09 | 2017-05-18 | Forge Therapeutics, Inc. | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections |
| EP3374355A4 (en) | 2015-11-09 | 2019-04-17 | Forge Therapeutics, Inc. | COMPOUNDS BASED ON PYRONE AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS |
| AU2016374416A1 (en) | 2015-12-15 | 2018-06-14 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| EP3478671B1 (en) | 2016-06-29 | 2020-05-13 | H. Hoffnabb-La Roche Ag | Pyridazinone-based broad spectrum anti-influenza inhibitors |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JP6692113B2 (ja) * | 2016-10-21 | 2020-05-13 | 塩野義製薬株式会社 | ６員複素環誘導体を含有する医薬組成物 |
| EP3621962A4 (en) | 2017-05-10 | 2020-12-09 | Forge Therapeutics, Inc. | ANTIBACTERIAL COMPOUNDS |
| MX2020002869A (es) | 2017-09-15 | 2020-07-24 | Aduro Biotech Inc | Compuestos de pirazolopirimidinona y usos de los mismos. |
| IL281614B2 (en) * | 2018-09-20 | 2024-12-01 | Blacksmith Medicines Inc | Antibacterial compounds |
| PT3891145T (pt) | 2018-12-06 | 2023-07-18 | Constellation Pharmaceuticals Inc | Moduladores de trex1 |
| WO2021195258A1 (en) * | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor, formulations, and uses thereof |
| WO2021195260A1 (en) | 2020-03-25 | 2021-09-30 | Forge Therapeutics, Inc. | Lpxc inhibitor and methods of making |
| FI4210700T3 (fi) | 2020-09-09 | 2025-09-16 | Crinetics Pharmaceuticals Inc | Somatostatiinimodulaatorin formulaatioita |
| AU2022269596A1 (en) * | 2021-05-05 | 2023-11-16 | Constellation Pharmaceuticals, Inc. | Modulators of trex1 |
| JP2024536864A (ja) | 2021-09-28 | 2024-10-08 | ブラックスミス メディシンズ，インク． | Ｌｐｘｃ阻害剤およびその使用 |
| WO2025264724A1 (en) * | 2024-06-20 | 2025-12-26 | The Regents Of The University Of California | Mpro inhibitors and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035076A1 (en) * | 2001-10-26 | 2003-05-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| WO2003035077A1 (en) * | 2001-10-26 | 2003-05-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| EP1698628A1 (en) * | 2003-12-22 | 2006-09-06 | Shionogi Co., Ltd. | Hydroxypyrimidinone derivative having hiv integrase inhibitory activity |
| WO2012088283A1 (en) * | 2010-12-23 | 2012-06-28 | Baylor College Of Medicine | Small molecule compounds as broad-spectrum inhibitors of metallo-beta-lactamases |
| CN102617487A (zh) * | 2012-03-02 | 2012-08-01 | 北京工业大学 | 多取代嘧啶酮类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| AU2003262946A1 (en) | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| MXPA06007906A (es) | 2004-01-12 | 2007-02-14 | Gilead Sciences Inc | Compuestos antivirales de fosfonato de pirimidilo y metodos de uso. |
| CN101014572B (zh) | 2004-09-15 | 2011-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物 |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| WO2011046920A1 (en) | 2009-10-12 | 2011-04-21 | Baylor College Of Medicine | Novel dxr inhibitors for antimicrobial therapy |
| WO2012151567A1 (en) * | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| CN102911124B (zh) | 2012-10-25 | 2015-11-25 | 山东大学 | 羟基嘧啶酮类化合物及其制备方法与应用 |
-
2013
- 2013-08-05 KR KR20157005600A patent/KR20150039832A/ko not_active Withdrawn
- 2013-08-05 EP EP13759141.8A patent/EP2885289A1/en not_active Withdrawn
- 2013-08-05 US US13/958,913 patent/US8921388B2/en not_active Expired - Fee Related
- 2013-08-05 WO PCT/EP2013/066388 patent/WO2014023691A1/en not_active Ceased
- 2013-08-05 CN CN201380041462.1A patent/CN104619699A/zh active Pending
- 2013-08-05 CA CA2879245A patent/CA2879245A1/en not_active Abandoned
- 2013-08-05 HK HK15111131.0A patent/HK1210177A1/xx unknown
- 2013-08-05 MX MX2015001478A patent/MX2015001478A/es unknown
- 2013-08-05 JP JP2015525852A patent/JP2015524457A/ja active Pending
- 2013-08-05 RU RU2015107803A patent/RU2015107803A/ru not_active Application Discontinuation
- 2013-08-05 HK HK15112102.3A patent/HK1211289A1/xx unknown
- 2013-08-05 BR BR112015002516A patent/BR112015002516A2/pt not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035076A1 (en) * | 2001-10-26 | 2003-05-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| WO2003035077A1 (en) * | 2001-10-26 | 2003-05-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| EP1698628A1 (en) * | 2003-12-22 | 2006-09-06 | Shionogi Co., Ltd. | Hydroxypyrimidinone derivative having hiv integrase inhibitory activity |
| WO2012088283A1 (en) * | 2010-12-23 | 2012-06-28 | Baylor College Of Medicine | Small molecule compounds as broad-spectrum inhibitors of metallo-beta-lactamases |
| CN102617487A (zh) * | 2012-03-02 | 2012-08-01 | 北京工业大学 | 多取代嘧啶酮类化合物及其制备方法和应用 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109503528A (zh) * | 2018-05-15 | 2019-03-22 | 天津国际生物医药联合研究院 | 一种化合物及其在抗沙粒病毒感染中的应用 |
| CN109503528B (zh) * | 2018-05-15 | 2022-06-14 | 天津国际生物医药联合研究院 | 一种化合物及其在抗沙粒病毒感染中的应用 |
| CN109897007A (zh) * | 2019-02-25 | 2019-06-18 | 天津国际生物医药联合研究院 | 二羟基嘧啶化合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014023691A1 (en) | 2014-02-13 |
| RU2015107803A (ru) | 2016-09-27 |
| EP2885289A1 (en) | 2015-06-24 |
| JP2015524457A (ja) | 2015-08-24 |
| US20140038990A1 (en) | 2014-02-06 |
| US8921388B2 (en) | 2014-12-30 |
| CA2879245A1 (en) | 2014-02-13 |
| BR112015002516A2 (pt) | 2017-07-04 |
| HK1210177A1 (en) | 2016-04-15 |
| MX2015001478A (es) | 2015-08-12 |
| HK1211289A1 (en) | 2016-05-20 |
| KR20150039832A (ko) | 2015-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104619699A (zh) | 二羟基嘧啶碳酸衍生物以及它们在治疗、改善或预防病毒疾病中的用途 | |
| CN104334563B (zh) | 7‑氧代‑噻唑并吡啶碳酸衍生物和它们在治疗、改善或预防病毒疾病中的用途 | |
| CN104507481B (zh) | 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物 | |
| CN103958521B (zh) | 嘧啶-4-酮衍生物及其在治疗、减轻或预防病毒疾病中的用途 | |
| CN103958475B (zh) | 杂芳基异羟肟酸衍生物及其在治疗、减轻或预防病毒疾病中的用途 | |
| JP2016518305A (ja) | ピリミドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 | |
| US8952039B2 (en) | Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease | |
| CN107074880A (zh) | 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途 | |
| WO2017046318A1 (en) | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease | |
| CN104903319B (zh) | 萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途 | |
| WO2017046362A1 (en) | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease | |
| CN107001355A (zh) | 吡啶并吡嗪化合物和它们在治疗、改善或预防流感中的用途 | |
| HK1199881B (en) | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1210177 Country of ref document: HK |
|
| AD01 | Patent right deemed abandoned | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20180622 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1210177 Country of ref document: HK |